30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
In a two-part series, Michael Volkov examines the continuing problem of identifying and mitigating b...
Read More >
Welcome to the first day of a five-day podcast series Jay Rosen and I are releasing in honor of the ...
Read More >
2020 AG Elections -Republican John Westercamp Announces Candidacy for Indiana Attorney General -Jo...
Read More >
A recent decision by the Competition Appeal Tribunal (CAT), Tobii AB (publ) v. Competition and Marke...
Read More >
Senators Chris Murphy (D-Conn.) and Todd Young (R-Ind.) have introduced legislation entitled the Wor...
Read More >
Il Ministero dell’Economia e delle Finanze, Dipartimento del Tesoro (“MEF”) ha da qualche giorno ...
Read More >